tbuckley/cabot-search huggingface dataset:
Prognostic model of lower grade gliomas.
Authors: Kosuke Aoki, Hiromichi Suzuki, Hideo Nakamura, Kazuya Motomura, Masahiro Mizoguchi, Tatsuya Abe, Yoshihiro Muragaki, Toshihiko Wakabayashi, Seishi Ogawa, Atsushi Natsume
Journal: Journal of Clinical Oncology (2015)

2038 Background: Lower grade gliomas (LGGs, WHO grade II/III gliomas) account for one third of all gliomas. Most LGGs generally show a slow progression, but some show a more aggressive clinical course. Large-scale and comprehensiveness in genetical and clinical studies enables establishment of a reliable prognostication system. Methods: Status of somatic mutations and copy number variations (CNVs) generated by whole exome/targeted sequencing and SNP array were investigated for 653 patients combined 269 Japanese patients with publically available 384 patients from the Cancer Genome Atlas, who were randomly divided into training (327 patients) and validation sets (326 patients). LGGs were genetically classified into 3 types according to IDH mutation and 1p/19q loss of heterozygosity (LOH): Type 1 (mutated IDH with 1p/19q LOH), Type 2 (mutated IDH without 1p19q LOH), and Type 3 (IDH wild type) which also were well correlated with overall survival (OS) (Nature Genetics, in press). In the current study, we sought significant risk factors in each LGG type contributing OS using Cox regression analysis and Akaike information criterion. We validated the accuracy of this classifier in the validation set. Results: In the training set, significant risk factors were extracted in Types 1 and 3, but not in Type 2. These types were sub-grouped into low- and high-risk groups ( HR = 3.13, 2.81 and 95% CI = 1.36-7.19, 1.25-6.32 respectively). Eventually, all LGGs were divided into low- and intermediate- and high-risk group, showing significantly different OS. The performance of the new model was evaluated by receiver operator characteristic analysis, which showed significantly higher accuracy than previously reported clinical/histological parameters, in particular for long-term prognosis. Conclusions: We established a new classifier based on genetic parameters, which provides a reliable tool for predicting OS in LGG patients and should be useful to guide an individual molecular-targeted therapy.
The effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer treated with chemoradiation: A report of the Radiation Therapy Oncology Group (RTOG) 0617.
Authors: Bree Ruppert Eaton, Stephanie L. Pugh, Jeffrey D Bradley, Vivek Kavadi, Samir Narayan, Lucien Alexander Nedzi, Cliff Grant Robinson, Melvin Deutsch, Christoper D. Koprowski, Douglas W. Johnson, JoAnne Meng, Walter J. Curran
Journal: Journal of Clinical Oncology (2014)

7551 Background: This analysis evaluates the potential association between institutional clinical trial accrual volume and the outcome of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving chemoradiation therapy (CRT) on a phase III trial (RTOG 0617). Methods: Patients with LA-NSCLC were randomized to 60 Gy vs. 74 Gy with concurrent carboplatin and paclitaxel +/- cetuximab, with initial results reported at ASCO 2013 (abst # 7501) and IASLC 2013. Participating institutions were divided into tertiles based on accrual to RTOG 0617. Those within the two lowest accrual tertiles were categorized as low volume centers (LVC), and those within the highest accrual tertile were categorized as high volume centers (HVC). Results: Range of accrual for LVC (n=195) vs. HVC (n=300) was 1-3 vs. 4-18 patients. Patients treated at HVC were more likely to be treated with intensity modulated RT (54.0% vs. 39.5%, p=0.002), to have a lower mean esophageal RT dose (26.1 Gy vs. 28.0 Gy, p=0.03), and to have a lower heart RT dose (V5Gy 38.2% vs. 54.1%, p<0.001; and V50Gy 3.6% vs. 7.3%, p<0.001). All other clinical variables were similar between the two cohorts. Treatment at a HVC was associated with significantly better OS and PFS compared with treatment at a LVC, median OS: 26.2 months vs. 19.8 months (HR 0.7, 95% CI 0.56 – 0.88, p=0.002), and median PFS: 11.4 months vs. 9.7 months (HR 0.80, 95% CI 0.65 – 0.99, p=0.04). HVC remained favorably associated with both OS (p=0.013) and PFS (p=0.028) when accounting for other factors. Additional factors associated with better OS were 60 Gy dose level (p=0.006), low heart V5Gy (p=0.003), and upper lobe tumor location (p=0.014); and with better PFS were 60 Gy dose level (p=0.006) and low heart V5Gy (p=0.004). Patients treated at HVC had a lower incidence of grade 5 adverse events (AEs) (5.3% vs. 9.2%, p=0.09) and were less likely to have RT terminated due to AEs (1.3% vs. 4.1%, p=0.07) than those treated at LVC. Conclusions: Treatment at institutions with higher clinical trial accrual was associated with better OS and PFS among patients with LA-NSCLC participating in a phase III trial. Clinical trial information: NCT00533949.
18F-NaF PET/CT in Extensive Melorheostosis of the Axial and Appendicular Skeleton With Soft-Tissue Involvement
Authors: Georgios Z. Papadakis, Smita Jha, Timothy Bhattacharyya, Corina Millo, Tsang-Wei Tu, Ulas Bagci, Kostas Marias, Apostolos H. Karantanas, Nicholas J. Patronas
Journal: Clinical Nuclear Medicine (2017)

Melorheostosis is a rare, nonhereditary, benign, sclerotic bone dysplasia with no sex predilection, typically occurring in late childhood or early adulthood, which can lead to substantial functional morbidity, depending on the sites of involvement. We report on a patient with extensive melorheostosis in the axial and appendicular skeleton, as well as in the soft tissues, who was evaluated with whole-body F-NaF PET/CT scan. All melorheostotic lesions of the skeleton and of the ossified soft-tissue masses demonstrated intensely increased F-NaF activity, suggesting the application of this modality in assessing and monitoring the disease activity.
Sixty seconds on . . . flu
Authors: Anne Gulland
Journal: BMJ (2017)

It is, but if you were holed up in bed with aching joints, a sandpaper throat, and thumping headache this winter, you might blame the parents of small children. Researchers surveyed 1000 parents of children aged 2-7 years and found that during the 2015-16 flu season just half (52.8%) had their children vaccinated against flu.1 All UK children aged 2-4 and some older children are offered a nasal …
STATIN ELIGIBILITY IN PRIMARY PREVENTION: FROM A RISK-BASED STRATEGY TO A PERSONALIZED APPROACH BASED ON THE PREDICTED CARDIOVASCULAR BENEFIT
Authors: Fernando H.Y. Cesena, Antonio Laurinavicius, Viviane Tabone, Raquel Conceicao, Marcio Bittencourt, Raul Santos
Journal: Journal of the American College of Cardiology (2017)
EXTERNAL COOLING OF THE MYOCARDIUM SLOWS ELECTRICAL CONDUCTION AND TERMINATES ATRIAL FIBRILLATION
Authors: Chance M. Witt, Richard Sanders, Charles Ritrivi, Steve Berhow, Doug Beinborn, Gregory J. Seifert, Chad Zack, Dorothy Ladewig, Joanne M. Powers, Scott Suddendorf, Samuel Asirvatham, Paul Friedman
Journal: Journal of the American College of Cardiology (2017)
Severe zoledronic acid (ZOL)-associated hypophosphatemia and prognosis in patients with castration-resistant prostate cancer (CRPC).
Authors: Julia Warr, David Yam, Leah VanDraanen, Shannon Goodall, Angie Giotis, Mark Pasetka, Pierre K Isogai, Alexandre Mamedov, Carlo DeAngelis, Urban Emmenegger
Journal: Journal of Clinical Oncology (2012)

e15180 Background: ZOL therapy is associated with severe (i.e., grade ≥ 3) hypocalcemia and hypophosphatemia in a subset of patients with metastatic CRPC. However, as opposed to the distinct clinical picture of hypocalcemia, the symptoms of hypophosphatemia are less pathognomonic. Furthermore, serum phosphate abnormalities are not regularly reported. Methods: To characterize the rate and clinical impact of severe hypophosphatemia in CRPC patients undergoing ZOL therapy, we identified CRPC patients receiving at least 3 doses of ZOL at our Centre between 01/2004 and 03/2011. Patient demographics, disease characteristics and laboratory parameters were extracted using the Oncology Symptom Control and Information Resource database, and by means of manual chart review. Results: 12 of 90 evaluable patients developed grade ≥ 3 hypophosphatemia (nadir) after 364±299 days (mean±SD) following the first dose of ZOL. While only one patient presented with concomitant severe hypocalcemia, the hypophosphatemia nadir coincided with rising PSA readings in 9 out of 11 informative patients. Severe ZOL-associated hypophosphatemia identified patients with worse outcome (median overall survival from time of CRPC diagnosis to death 685 days) compared to patients without documented hypophosphatemia (907 days, HR 0.52, p=0.049; n=42), or patients with grade 1-2 hypophosphatemia (1035 days, HR 0.44, p=0.016; n=36). Otherwise, the prognostic nomogram developed by Armstrong et al appears not to capture the poor prognosis of patients with severe ZOL-associated hypophosphatemia. Conclusions: Grade 3-4 hypophosphatemia occurs in about 15% of CRPC patients undergoing ZOL therapy and is associated with worse prognosis when compared to patients with absent or mild hypophosphatemia. The latter is usually transient and likely related to increased parathyroid hormone levels due to calcium decreases as a consequence of bisphosphonate therapy. On the other hand, the distinct clinical behavior of CRPC presenting with ZOL-associated severe hypophosphatemia suggests that secreted tumor-associated factors such as fibroblast growth factor 23 may contribute to this phenomenon.
IMMUNO-HISTOPATHOLOGY OF INTRACORONARY THROMBUS ASPIRATED DURING PRIMARY PERCUTANEOUS INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION AND ITS CLINICAL SIGNIFICANCE
Authors: Neeraj Parakh, Basavaraj Utagi, Sudhir Arava, Sunil Verma, Ganesan Karthikeyan, Sandeep Singh, Balram Bhargava, Ruma Ray, Chetan D. Patel, Vinay Bahl
Journal: Journal of the American College of Cardiology (2017)
RETROSPECTIVE ANALYSIS OF THROMBOGENIC BIOMARKERS IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH NOVEL ORAL ANTICOAGULANTS
Authors: Jeffrey Liles, Christopher Wanderling, Sallu Jabati, Timothy Rowe, Abigail Otto, Jack Bonteckoe, Debra Hoppensteadt, Mushabbar Syed, Jawed Fareed
Journal: Journal of the American College of Cardiology (2017)
EFFICACY OF PHOSPHODIESTERASE-5 INHIBITOR IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: A META-ANALYSIS
Authors: Anurag Bajaj, Sukrut Nanavaty, John Coppola, Hemant Tiwari, Tejas Patel, Samir Pancholy
Journal: Journal of the American College of Cardiology (2017)
HER2 status testing by immunohistochemical and fFluorescence in situ hybridization in China
Authors: W. Tao, J. Zefei, Z. Xuan, L. Xiaobing, Z. Shaohua, S. Ge, Z. Min, W. Shikai, S. Santai
Journal: Journal of Clinical Oncology (2009)

e22233 Background: HER2 gene overexpression is associated with aggressive breast cancer and poor clinical prognosis. Humanized anti-HER2 monoclonal antibody trastuzumab, which is targeted HER2 protein has showed to improve overall survival in patients with HER2-positive breast cancer in both the metastatic and adjuvant settings. There are some differences in HER2 positive rate among difference reports in China. This study tested HER2 status by immunohistochemistry(IHC) and fluorescence in situ hybridization (FISH) and compared HER2 testing at central and regional laboratories in China. Methods: Assessment of HER2 status was performed by FISH using the HercepTeast kit at central laboratory and by IHC using commercial available anti-HER2 probe in formalin-fixed and paraffin-embedded tissue section of 280 breast cancer samples. IHC HER2 testing was performed on 149 samples in the central laboratory. IHC HER2 testing was performed on 80 samples at both central laboratory and regional laboratory. Results: 280 samples were tested 373 times testing by IHC and FISH. The results were showed in table 1 . 80 samples was tested by IHC at central and regional laboratory and testing results of 36.4% samples were accordant (K=0.038). 94.1% IHC3+ at central laboratory were HER2 FISH positive and 83.3% IHC 3+ at regional laboratory were HER2 FISH positive. 86.7% IHC 2+ at central laboratory were HER2 FISH positive and 62.7% IHC 2+ at regional laboratory were HER2 FISH positive. 17 samples were observed HER2 FISH positive in the 27 IHC 0/1+ tested at regional laboratoty. So good correlation was obsearved between FISH HER2 status and IHC results from central laboratory but not from regional laboratory. Conclusions: This study emphasized the important of accurate HER2 testing. HER2 FISH test should be performed for the IHC 2+ samples. Even HER2 FISH test maybe performed for IHC 0/1 sample according to clinical characteristics in China in order to make the patients have targeted therapy chance. [Table: see text] No significant financial relationships to disclose.
UNDERUSE OF POTENT ORAL P2Y12 INHIBITORS IN WOMEN WITH AN ACUTE CORONARY SYNDROME, DESPITE HAVING A HIGHER RISK PROFILE THAN MALE PATIENTS
Authors: Ana Marcano, David Vivas, Juan Carlos Gomez-Polo, Antonio Tello, Jesus De La Hera, Francisco Marin, Inmaculada Roldan, Jose Luis Ferreiro
Journal: Journal of the American College of Cardiology (2017)
THE IMPACT OF NATURAL CHIOS MASTIC SUPPLEMENTATION ON ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS IN SMOKERS
Authors: Vasiliki Tsigkou, Gerasimos Siasos, Evangelos Oikonomou, Konstantinos Mourouzis, George-Angelo Papamikroulis, Eleni Kokkou, Georgia Vogiatzi, Nikolaos Gouliopoulos, Sotirios Tsalamandris, Nikolaos Papageorgiou, Savvas Mazaris, Manolis Vavuranakis, Christodoulos I. Stefanadis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
HIGH-DOSE HUMANIN ANALOGUE APPLIED DURING ISCHEMIA PROVIDES CARDIOPROTECTION AGAINST ISCHEMIA-REPERFUSION INJURY THROUGH ATTENUATING MITOCHONDRIAL DYSFUNCTION
Authors: Savitree Thummasorn, Krekwit Shinlapawittayatorn, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2017)
THE CORRELATES AND PROGNOSTIC IMPACT OF PULMONARY ARTERIAL PULSE PRESSURES, DIASTOLIC AND TRANSPULMONARY PRESSURE GRADIENTS IN PULMONARY HYPERTENSION: INSIGHTS FROM EUPHRATES STUDY
Authors: Cihangir Kaymaz, Aykun Hakgor, Hacer Ceren Tokgoz Demircan, Ozgur Akbal, Ibrahim Halil Tanboga, Fatih Yilmaz, Canan Elif Yildiz, Sevim Turkday, Nertila Poci, Tugba Aktemur, Durmus Demir, Seda Tanyeri, Nihal Ozdemir
Journal: Journal of the American College of Cardiology (2017)
SCREENING OF PATIENTS WITH SIMPLE CLINICAL PARAMETERS EARLY IN HOSPITALIZATION IS HIGHLY SENSITIVE FOR DETECTION OF HEART FAILURE HOSPITALIZATION
Authors: Robin Fortman, Gopi Astik, Preeti Kansal, Hannah Alphs Jackson, Daniel Navarro, Allen Anderson, Charles Davidson, Clyde Yancy, Raja Mutharasan
Journal: Journal of the American College of Cardiology (2017)
Correlation of decreased pS6 expression under MEK inhibitor (MEKi) with response to MEKi alone or combined with PI3K-mTOR inhibitor (PI3Ki-mTORi) in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models.
Authors: Cindy Neuzillet, Annemilai Tijeras-Raballand, Jerome Cros, Pierre Bourgoin, Philippe Bourget, Maria Serova, Armand De Gramont, Sandrine J. Faivre, Eric Raymond, Philippe B. Ruszniewski, Pascal Hammel
Journal: Journal of Clinical Oncology (2015)

e15262 Background: MEKi are under clinical evaluation in combination with other agents including PI3Ki-mTORi. RAS/RAF mutations, EMT, PI3K-mTOR activation, and pERK inhibition during treatment have been suggested as predictive markers for MEKi, but remain unvalidated in PAC. We explored the cellular and molecular effects of MEKi GSK1120212 (GSK212) alone or combined with PI3Ki-mTORi in PAC cell lines and ex vivo system. Methods: GSK212 is a non-ATP competitive MEKi, Everolimus (Ev) a mTORi, and BKM120 a pan-PI3Ki. Proliferation was evaluated by MTT assay and drug combinations analyzed by the Chou-Talalay method. Protein expression was assessed by Western blot and immunochemistry. Ex vivo study consisted in 48h cultures of fresh tissue slices from patient surgical specimens. Apoptosis and proliferation were evaluated by caspase 3 and Ki67 immunostaining, respectively. Results: MIAPaCa-2 and PANC-1 are two mesenchymal KRAS mut/BRAF wild-type PAC cell lines with different response to GSK212, MIAPaCa-2 being sensitive and PANC-1 resistant (IC50 = 0.009µM vs 33µM). MIAPaCa-2 was more sensitive than PANC-1 to Ev (IC50 = 23.3µM vs 47.0µM) and BKM120 (IC50 = 4.19µM vs 31.6µM). Combination of GSK212 and Ev or BKM120 was synergistic only in MIAPaCa-2. GSK212 (0.1µM) resulted in pERK extinction in both cell lines but pS6 was decreased only in MIAPaCa-2. Combination therapy resulted in pERK and pS6 extinction in both cell lines. Apoptosis in MIAPaCa-2 was confirmed by PARP cleavage. Two tumor specimens were cultured ex vivo: (a) GSK212 (0.1 µM) alone induced apoptosis concomitantly with pS6 decrease; (b) Ev (1µM) or BKM120 (0.1µM) alone exerted antiproliferative but no cytotoxic effects; (c) combinations resulted in higher caspase 3 levels and decrease pS6 than MEKi alone. Linear regression showed significant correlation between caspase 3 and pS6. The analysis of 4 additional tumors and RAS mutation status will be presented. Conclusions: Response to MEKi/mTORi combination was not correlated with “classical” markers of response to MEKi. Decrease in pS6 may be an early monitoring biomarker for MEKi and MEKi/mTORi combination.
IMPROVEMENT IN CHOLESTEROL EFFLUX CAPACITY IS ASSOCIATED WITH IMPROVEMENT IN VASCULAR INFLAMMATION BY 18- FDG PET CT IN PSORIASIS
Authors: Aditya A. Joshi, Amit Dey, Abhishek Chaturvedi, Jonathan Chung, Joshua Rivers, Mohammad Tarek Kabbany, Mark Ahlman, Martin Playford, Nehal Mehta
Journal: Journal of the American College of Cardiology (2017)
Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features
Authors: P. Cejas, M. López-Gómez, R. Madero, J. De Castro, E. Casado, C. Belda, J. Larrauri, J. Barriuso, M. González-Barón, J. Feliú
Journal: Journal of Clinical Oncology (2009)

4053 Background: K-Ras mutations in CRC primaries may predict resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, but we don´t know its behaviour in metastatic tissue. The aims of this study were: 1) Evaluate the grade of concordance of K-Ras status between primary and related metastatic samples 2) Establish a correlation between k-ras status and individual clinicopathological features Methods: K-ras mutations were retrospectively analysed in primary tumours of 124 patients and 138 related metastatic sites. The primary tumour site was colon in 87 patients and rectum in 37. Sites of metastases were liver (115 samples,83.3%) and lung (23 samples,16.7%). Some patients underwent surgery several times. We analyzed K-Ras point mutations in codons 12 and 13 by direct DNA sequencing from paraffin-embedded tumour and studied its relation with 13 clinicopathological features Results: K-Ras mutation was observed in 42(33.6%) primary tumours and in 52(39.1%) related metastatic sites, being the grade of concordance between primary and metastatic sites of 93% (95% CI: 97.5–88.3%). Discordance was observed in 9 (7%) patients: in 2, K-Ras status was wild type in metastatic site and expressed a mutational pattern in the primary tumour; vice versa, in 7, the mutation status was detected in the metastases meanwhile primary tumour was wild type. We also found statistically significative differences in mutation patterns regarding the site of the metastasic tissue: K-ras mutations were detected in 13 lung samples (61.9%) and in 39 liver samples (34.8%) (p=0.028). Of all the clinicopathological features analyzed we confirmed an increase of mutated K-ras status in tumours which had presented as perforation (p=0.044). No other relation with clinicopathological data was detected Conclusions: With this observational analysis, we confirm the high concordance (superior to 90%) between primary and related metastatic sites in terms of K-Ras status; for the first time, we have reported a higher mutational pattern in lung metastases than in liver disease, founds that may have important relevance regarding clinical/treatment decisions. For the realization of this study we received a grant from Amgen. No significant financial relationships to disclose.
CHEST PAIN IN A PATIENT WITH ANOMALOUS LEFT ANTERIOR DESCENDING CORONARY ARTERY, MYOCARDIAL BRIDGING AND VASOCONSTRICTION: IDENTIFICATION OF THE CULPRIT ETIOLOGY AND MANAGEMENT OF A CHALLENGING COMBINATION
Authors: Michel Corban, Amy Pollak, Amir Lerman, Naser Ammash
Journal: Journal of the American College of Cardiology (2017)
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Authors: Stephan B. Dreyer, David K. Chang, Peter Bailey, Andrew V. Biankin
Journal: Clinical Cancer Research (2017)

Abstract Pancreatic cancer has become the third leading cause of cancer-related death, with little improvement in outcomes despite decades of research. Surgery remains the only chance of cure, yet only 20% of patients will be alive at 5 years after pancreatic resection. Few chemotherapeutics provide any improvement in outcome, and even then, for approved therapies, the survival benefits are marginal. Genomic sequencing studies of pancreatic cancer have revealed a small set of consistent mutations found in most pancreatic cancers and beyond that, a low prevalence for targetable mutations. This may explain the failure of conventional clinical trial designs to show any meaningful survival benefit, except in small and undefined patient subgroups. With the development of next-generation sequencing technology, genomic sequencing and analysis can be performed in a clinically meaningful turnaround time. This can identify therapeutic targets in individual patients and personalize treatment selection. Incorporating preclinical discovery and molecularly guided therapy into clinical trial design has the potential to significantly improve outcomes in this lethal malignancy. In this review, we discuss the findings of recent large-scale genomic sequencing projects in pancreatic cancer and the potential relevance of these data to therapeutic development. Clin Cancer Res; 23(7); 1638–46. ©2017 AACR. See all articles in this CCR Focus section, “Pancreatic Cancer: Challenge and Inspiration.”
Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression
Authors: Kei Kimura, Yuko Kuroda, Yuta Masuda, Arito Yamane, Hikaru Hattori, Kenichi Tahara, Ayaka Kaneko, Itsumi Suda, Noriyuki Takahashi, Nanami Gotoh, Kie Nagai, Tomomi Nagashima, Takayuki Saitoh, Hirono Iriuchishima, Makiko Takizawa, Hiromi Koiso, Takuma Ishizaki, Takeki Mitsui, Hiroaki Shimizu, Akihiko Yokohama, Norifumi Tsukamoto, Tetsuhiro Kasamatsu, Yusuke Minato, Yoshihisa Nojima, Hirokazu Murakami, Hiroshi Handa
Journal: Blood (2015)
EFFICACY OF SCATTERGRAM ANALYSIS FOR CLASSIFYING SUBTYPES OF ATRIAL FIBRILLATION BY FOURIER TRANSFORM OF FIBRILLATORY WAVES
Authors: Sungsoo Kim, Sohee Kwon, Ira Blau, Junbeom Park, Moon-Hyoung Lee, Lindsey Krawchuk, Nicholas Meyers, Byung-Il Choi
Journal: Journal of the American College of Cardiology (2017)